The Children's Hospital of Philadelphia has found new hope for babies and toddlers suffering from neuroblastoma, a rare but deadly cancer, in a pair of studies, reports USA Today.
Both therapies offer better, safer treatments for the disease, and belong to the emerging field of "personalized" cancer therapy, with medications tailored to the specific genetic profiles of a patient's tumor, says co-author John Maris of the Children's Hospital of Philadelphia.A study of 226 children focused on an experimental, man-made antibody, called ch14.18, given as a cocktail with other immune stimulants. Doctors randomly assigned half of children to get standard care and half to receive the new antibody, according to the study in today's New England Journal of Medicine.Original source: USA Today
Read the full story here.